Zuranolone

Zuranolone
Clinical data
Pronunciation	/zʊˈrænəloʊn/; zuu-RAN-ə-lohn
Trade names	Zurzuvae
Other names	SAGE-217; S-812217; SGE-797; BIIB-125
License data	US DailyMed: Zuranolone;
Pregnancy; category	Contraindicated;
Routes of; administration	By mouth
Drug class	Neurosteroid; GABAA receptor positive allosteric modulator
ATC code	N06AX31 (WHO) ;
Legal status
Legal status	US: Schedule IV;
Pharmacokinetic data
Protein binding	99.5%
Metabolism	CYP3A4
Elimination half-life	16–23 hours
Identifiers
	IUPAC name 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile;
CAS Number	1632051-40-1;
PubChem CID	86294073;
DrugBank	DB15490;
ChemSpider	71117610;
UNII	7ZW49N180B;
KEGG	D11793;
ChEBI	CHEBI:228302;
ChEMBL	ChEMBL4105630;
ECHA InfoCard	100.271.331
Chemical and physical data
Formula	C25H35N3O2
Molar mass	409.574 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(CN1N=CC(C#N)=C1)[C@H]2CC[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@](C)(O)CC[C@]5([H])[C@@]4([H])CC[C@@]32C;
	InChI InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1; Key:HARRKNSQXBRBGZ-GVKWWOCJSA-N;

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth.

The most common side effects include drowsiness, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection. An orally active inhibitory pregnane neurosteroid, zuranolone acts as a positive allosteric modulator of the GABA_A receptor.

Zuranolone was approved for medical use in the United States for the treatment of postpartum depression in August 2023. It was developed by Sage Therapeutics and Biogen.

Clinical data


Pronunciation	/zʊˈrænəloʊn/ zuu-RAN-ə-lohn
Trade names	Zurzuvae
Other names	SAGE-217; S-812217; SGE-797; BIIB-125
License data	US DailyMed: Zuranolone
Pregnancy category	Contraindicated
Routes of administration	By mouth
Drug class	Neurosteroid; GABA_A receptor positive allosteric modulator
ATC code	N06AX31 (WHO)
Legal status
Legal status	US: Schedule IV
Pharmacokinetic data
Protein binding	99.5%
Metabolism	CYP3A4
Elimination half-life	16–23 hours
Identifiers
IUPAC name 1-(2-((3R,5R,8R,9R,10S,13S,14S,17S)-3-Hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl)-1H-pyrazole-4-carbonitrile
CAS Number	1632051-40-1
PubChem CID	86294073
DrugBank	DB15490
ChemSpider	71117610
UNII	7ZW49N180B
KEGG	D11793
ChEBI	CHEBI:228302
ChEMBL	ChEMBL4105630
ECHA InfoCard	100.271.331
Chemical and physical data
Formula	C₂₅H₃₅N₃O₂
Molar mass	409.574 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(CN1N=CC(C#N)=C1)[C@H]2CC[C@@]3([H])[C@]4([H])CC[C@]5([H])C[C@](C)(O)CC[C@]5([H])[C@@]4([H])CC[C@@]32C
InChI InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1 Key:HARRKNSQXBRBGZ-GVKWWOCJSA-N